Bioabsorbable Stents Market By Type (Polymer-Based, Metallic-Based, Hybrid), By Application (Coronary Artery Disease, Peripheral Artery Disease, Carotid Artery Disease), By End-Use (Hospitals, Clinics, Ambulatory Surgical Centers), By Mode of Delivery (Balloon-Expandable, Self-Expanding), and By Region; Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Bioabsorbable Stents Market was valued at USD 0.8 billion in 2023 and will surpass USD 1.5 billion by 2030; growing at a CAGR of 8.9% during 2024 - 2030.

The bioabsorbable stents market is witnessing significant growth, driven by the increasing prevalence of cardiovascular diseases and the demand for more advanced, less invasive treatment options. Bioabsorbable stents are designed to temporarily support blood vessels after a blockage, allowing for natural healing over time as the stent material dissolves. These stents provide several advantages over traditional metal stents, including a reduced risk of long-term complications such as restenosis (re-narrowing of the artery) and thrombosis (blood clots). Additionally, bioabsorbable stents offer the benefit of being absorbed by the body, eliminating the need for permanent implants, which is a significant advantage for patients requiring ongoing treatment.

As the demand for minimally invasive procedures continues to rise, bioabsorbable stents are gaining traction in the treatment of coronary artery disease (CAD), peripheral artery disease (PAD), and carotid artery disease (CAD). The ability to treat patients with a stent that dissolves after the vessel heals is transforming the landscape of vascular interventions, making the bioabsorbable stents market one of the most promising areas within the broader cardiovascular medical devices market.

Polymer-Based Bioabsorbable Stents Are Dominating Due to Superior Biocompatibility

Polymer-based bioabsorbable stents are the dominant segment in the bioabsorbable stents market, owing to their superior biocompatibility and ability to be custom-designed for different clinical needs. These stents are made from bioabsorbable polymers that are gradually absorbed by the body, providing temporary support to the arterial wall after angioplasty or stent placement. The gradual absorption reduces the risk of long-term complications associated with traditional metal stents, such as inflammation or foreign body reactions.

The polymer-based stents offer several advantages, including flexibility, ease of delivery, and the ability to degrade at a controlled rate, which is crucial for ensuring optimal healing of the artery. As advancements in polymer technology continue, the design and functionality of these stents are improving, making them the preferred choice for many cardiovascular procedures. Furthermore, the increasing emphasis on biocompatibility and patient safety is expected to further strengthen the position of polymer-based stents in the market.

Coronary Artery Disease Application Leads Market Growth Due to High Prevalence

The coronary artery disease (CAD) application is the largest and fastest-growing segment in the bioabsorbable stents market, driven by the high prevalence of CAD and the increasing demand for effective treatment options. CAD, which occurs when the coronary arteries become narrowed or blocked, is one of the leading causes of heart attacks and other cardiovascular complications worldwide. As the global burden of cardiovascular diseases continues to rise, the need for advanced treatments such as bioabsorbable stents is also increasing.

Bioabsorbable stents have proven to be effective in treating CAD by providing temporary support to the coronary artery, allowing for natural healing without the long-term risks associated with metal stents. As the patient population for CAD continues to grow, particularly among aging populations, the demand for bioabsorbable stents in this application is expected to continue rising. Furthermore, ongoing clinical trials and technological advancements in bioabsorbable stent design are likely to drive further market growth in the CAD segment.

Hospitals Are the Largest End-Use Segment Due to High Patient Volume

The hospitals end-use segment is the largest in the bioabsorbable stents market, as hospitals are the primary setting for cardiovascular interventions, particularly in high-complexity cases. Hospitals have the necessary infrastructure, including skilled healthcare professionals and advanced medical equipment, to perform procedures involving bioabsorbable stents. The high patient volume in hospitals, especially in emergency and elective cardiovascular surgeries, makes them the primary end-user of these medical devices.

In addition to the growing patient demand, hospitals are increasingly adopting bioabsorbable stents due to their advantages over traditional stents, such as reduced risk of complications and the ability to support long-term healing. With the rise in cardiovascular diseases, hospitals are expected to continue to be the leading end-users of bioabsorbable stents, making this segment a key driver of market growth.

Balloon-Expandable Mode of Delivery Is Most Common Due to Ease of Use

The balloon-expandable mode of delivery is the most commonly used method for administering bioabsorbable stents. In this method, a balloon is inflated at the site of the blockage, expanding the stent and compressing it against the arterial walls. This technique is widely used because of its simplicity and effectiveness in achieving the desired arterial dilation. The balloon-expandable stent delivery system allows for precise placement of the stent, ensuring that it supports the artery as it heals.

As the demand for minimally invasive procedures grows, balloon-expandable stents are expected to remain the most widely used method of delivery, especially for coronary artery disease interventions. The ongoing advancements in balloon-expandable stent technology, including improvements in balloon catheter designs, are likely to further enhance the adoption of this delivery method in the coming years.

North America Is the Largest Market Due to Advanced Healthcare System

North America is the largest market for bioabsorbable stents, driven by the region's advanced healthcare system, high prevalence of cardiovascular diseases, and strong presence of key medical device manufacturers. The United States, in particular, dominates the market, with a well-established medical infrastructure and a high adoption rate of advanced medical technologies. The growing aging population in North America is contributing to the rise in cardiovascular diseases, which in turn increases the demand for innovative treatment options like bioabsorbable stents.

Additionally, the region's robust research and development activities, along with favorable regulatory frameworks, support the continuous advancement and commercialization of bioabsorbable stents. As healthcare providers in North America increasingly adopt bioabsorbable stents for treating cardiovascular diseases, the region will continue to lead the global market, with ongoing innovation and improvements in treatment outcomes further bolstering its position.

Competitive Landscape

The bioabsorbable stents market is highly competitive, with key players focusing on innovation, clinical trials, and regulatory approvals to maintain a competitive edge. Major companies in the market include Abbott Laboratories, Biotronik, Boston Scientific, and Medtronic, each of which has a significant presence in the bioabsorbable stent market. These companies are investing heavily in research and development to improve the performance, safety, and cost-effectiveness of their stent offerings.

The market is also characterized by the emergence of smaller, specialized players that are developing next-generation bioabsorbable stents, including hybrid materials and new polymer formulations. As the competition intensifies, collaborations and partnerships between medical device companies, research institutions, and healthcare providers are expected to drive further innovation. With the ongoing development of more effective and safe bioabsorbable stents, the competitive landscape will continue to evolve, creating new opportunities for market growth and transformation.

Recent Developments:

• In November 2024, Abbott Laboratories received approval for its new bioabsorbable stent for coronary artery disease, incorporating advanced polymer technology.
• In October 2024, Medtronic plc expanded its bioabsorbable stent portfolio with the introduction of a self-expanding stent for peripheral artery disease.
• In September 2024, Boston Scientific Corporation launched a new drug-eluting bioabsorbable stent designed to reduce restenosis in coronary artery patients.
• In August 2024, Biotronik SE & Co. KG announced a breakthrough in its bioabsorbable stent technology, improving its durability and absorption rate.
• In July 2024, Terumo Corporation expanded its distribution network for bioabsorbable stents in Europe, catering to an increasing demand for cardiovascular treatments.

List of Leading Companies:

• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic plc
• Biotronik SE & Co. KG
• Terumo Corporation
• Stentys S.A.
• Cardiovascular Systems, Inc.
• InspireMD, Inc.
• Vascular Concepts Ltd.
• Eucatech GmbH
• MIV Therapeutics, Inc.
• Endologix, Inc.
• Tokyo Medical University
• KANEKA Corporation
• Stryker Corporation

Report Scope: